ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 903,29
0,23%
DAX
17 932,17
-1,10%
Brent Oil
83,815
0,33%
Bitcoin
57 405,87
-1,43%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Elevation Oncology Inc (ELEV)

  7. Elevation Oncology Inc (ELEV) Actualités

ELEV Elevation Oncology Inc

4,0485
0,4985 (14,04%)
02 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Elevation Oncology Inc ELEV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,4985 14,04% 4,0485 01:05:31
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,59 3,43 4,48 4,00 3,55
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/4/202422:30PRNUSElevation Oncology Presents Preclinical Proof-of-Concept..
06/3/202414:14EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/3/202413:45EDGAR2Form 8-K - Current report
06/3/202413:30PRNUSElevation Oncology Reports Fourth Quarter and Full Year 2023..
06/3/202413:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202422:50PRNUSElevation Oncology to Present Preclinical Proof-of-Concept..
04/3/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202413:30PRNUSElevation Oncology Appoints Experienced Clinical Development..
28/2/202413:30PRNUSElevation Oncology to Participate in Upcoming Investor..
22/2/202413:30PRNUSElevation Oncology Expands Ongoing Phase 1 Clinical Trial of..
20/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202422:15EDGAR2Form 8-K - Current report
22/1/202422:57EDGAR2Form SC 13G - Statement of acquisition of beneficial..
22/1/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202422:24EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/1/202413:45EDGAR2Form 8-K - Current report
22/1/202413:30PRNUSElevation Oncology Announces Appointment of Darcy Mootz,..
09/1/202422:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/1/202413:40EDGAR2Form 8-K - Current report
05/1/202413:30PRNUSElevation Oncology Announces Program Updates and Upcoming..
22/11/202313:30PRNUSElevation Oncology to Present at the Piper Sandler 35th..
02/11/202312:45EDGAR2Form 8-K - Current report
02/11/202312:30PRNUSElevation Oncology Reports Third Quarter 2023 Financial..
02/11/202312:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22/9/202322:30EDGAR2Form 8-K - Current report
05/9/202313:30PRNUSElevation Oncology to Present at the H.C. Wainwright 25th..
16/8/202313:45EDGAR2Form 8-K - Current report
16/8/202313:30PRNUSElevation Oncology Announces First Patient Dosed in the..
03/8/202313:45EDGAR2Form 8-K - Current report
03/8/202313:30PRNUSElevation Oncology Reports Second Quarter 2023 Financial..
03/8/202313:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/8/202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/7/202322:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/7/202322:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/7/202314:15EDGAR2Form 8-K - Current report
13/7/202314:00PRNUSElevation Oncology Appoints Joseph Ferra as Chief Executive..
09/6/202304:41PRNUSElevation Oncology Announces Pricing of $50 Million Public..
08/6/202322:01PRNUSElevation Oncology Announces Launch of Proposed Public..
03/6/202315:00PRNUSElevation Oncology Highlights First-in-Human Phase 1..
15/5/202313:30PRNUSElevation Oncology Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
ELEV
Elevation Oncology
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés